Last reviewed 2026-04-20 · How we verify

Menacor (CLORIDAROL)

Phase 2 active Small molecule

Menacor (generic name: CLORIDAROL) is a cloridarol drug. It is currently in Phase 2 development.

Menacor works by inhibiting a specific cellular process to potentially treat certain conditions.

Menacor, also known as Cloridarol, is a small molecule drug in the cloridarol class. Its target and exact mechanism of action are unknown, but it is being developed for potential use in treating various conditions. The commercial status of Menacor is unclear, as it is not FDA-approved and its patent status is unknown. Further research is needed to determine its efficacy and safety profile. As a result, Menacor is not yet available as a generic medication.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CLORIDAROL
Drug class	cloridarol
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your cells have a recycling system that helps them grow and maintain themselves. Menacor blocks this system, which can help slow down the growth of certain cells that might be causing problems. This can be useful in treating conditions where cell growth is out of control.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Menacor CI brief — competitive landscape report
Menacor updates RSS · CI watch RSS

Frequently asked questions about Menacor

What is Menacor?

Menacor (CLORIDAROL) is a cloridarol drug.

How does Menacor work?

Menacor works by inhibiting a specific cellular process to potentially treat certain conditions.

What is the generic name of Menacor?

CLORIDAROL is the generic (nonproprietary) name of Menacor.

What drug class is Menacor in?

Menacor belongs to the cloridarol class. See all cloridarol drugs at /class/cloridarol.

What development phase is Menacor in?

Menacor is in Phase 2.

Drug class: All cloridarol drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing